The journey of patients affected by metastatic hormone receptor-positive/HER2-negative breast cancer from CDK 4/6 inhibitors to second-line treatment: A real-world analysis of 701 patients enrolled in the GIM14/BIOMETA studyChiara Molinelli, Lucia Del Mastro, Claudia Bighin et al.|European Journal of Cancer|2024Cited by 15
Clinico-pathological predictors of radiologic complete response to first-line anti-HER2 therapy in metastatic breast cancerLinda Cucciniello, Fabio Puglisi, Eva Blondeaux et al.|npj Breast Cancer|2024Cited by 2
Abstract PO4-04-05: HER2 immunohistochemistry (IHC) expression in HER2-positive (HER2-pos) metastatic breast cancer (mBC): clinical and prognostic differences between IHC 2+ and IHC 3+ populationsArianna Dri, Fabio Puglisi, Eva Blondeaux et al.|Cancer Research|2024Cited by 1
Clinico-pathological predictors of radiologic complete response to first-line anti-HER2 therapy in metastatic breast cancer: insights from real-world data of a nationwide cohortLinda Cucciniello, Fabio Puglisi, Eva Blondeaux et al.|Research Square|2024Cited by 0
Survival Outcomes of Luminal Metastatic Breast Cancer Patients According to Change of Molecular Subtype at Re-Biopsy. Insights from the GIM-13 - AMBRA StudyMarina Elena Cazzaniga, Giorgio Mustacchi, P. Pronzato et al.|Preprints.org|2025Cited by 0